Literature DB >> 12643698

A rare earth-DOTA-binding antibody: probe properties and binding affinity across the lanthanide series.

Todd M Corneillie1, Paul A Whetstone, Andrew J Fisher, Claude F Meares.   

Abstract

An antibody that binds rare earth complexes selectively could be used as a docking station for a set of probe molecules, of particular interest for medical imaging and therapy. The rare earths are rich in probe properties, such as the paramagnetism of Gd, the luminescence of Tb and Eu, and the nuclear properties of Lu and Y. We find that antibody 2D12.5, initially developed to bind analogues of Y-DOTA (1,4,7,10-tetraazacyclododecane-N,N',N' ',N' ''-tetraacetic acid) for radiotherapy, binds not only Y-DOTA analogues but also analogous DOTA complexes of all of the lanthanides. Surprisingly, chelates of some metals such as Gd3+ bind more tightly than the original Y3+ complex. When the shape of the complex is perturbed by either increasing or decreasing the radius of the lanthanide ion, the thermodynamic stability of the protein-ligand complex changes in a regular fashion. The behavior of DeltaDeltaG as a function of ionic radius fits a parabola, as might be expected for a system that behaves in a thermodynamically elastic way. The broad specificity and high affinity of this antibody for all rare earth-DOTA complexes make it particularly interesting for applications that take advantage of the unique characteristics of lanthanides. For example, UV excitation of the Tb-DOTA-2D12.5 complex leads to energy transfer from aromatic side chains of the antibody to bound Tb-DOTA, enhancing green terbium luminescence >104 relative to unbound Tb-DOTA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12643698     DOI: 10.1021/ja029363k

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  8 in total

Review 1.  The chemistry of irreversible capture.

Authors:  Claude F Meares
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

2.  Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.

Authors:  Jürgen Grünberg; Dennis Lindenblatt; Holger Dorrer; Susan Cohrs; Konstantin Zhernosekov; Ulli Köster; Andreas Türler; Eliane Fischer; Roger Schibli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-24       Impact factor: 9.236

3.  Rates and equilibria for probe capture by an antibody with infinite affinity.

Authors:  Tolulope A Aweda; Heather E Beck; Anna M Wu; Liu H Wei; Wolfgang A Weber; Claude F Meares
Journal:  Bioconjug Chem       Date:  2010-04-21       Impact factor: 4.774

4.  (111)In- and (203)Pb-Labeled Cyclic RGD Peptide Conjugate as an α(v)β(3) Integrin-Binding Radiotracer.

Authors:  Kido Nwe; Young-Seung Kim; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  J Labelled Comp Radiopharm       Date:  2012-09-05       Impact factor: 1.921

5.  Combination of isothermal titration calorimetry and time-resolved luminescence for high affinity antibody-ligand interaction thermodynamics and kinetics.

Authors:  Tolulope A Aweda; Claude F Meares
Journal:  Methods       Date:  2011-09-20       Impact factor: 3.608

6.  Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging.

Authors:  Kelly Davis Orcutt; Adrian L Slusarczyk; Maryelise Cieslewicz; Benjamin Ruiz-Yi; Kumar R Bhushan; John V Frangioni; K Dane Wittrup
Journal:  Nucl Med Biol       Date:  2010-10-27       Impact factor: 2.408

7.  Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex.

Authors:  Sarah M Cheal; Hong Xu; Hong-fen Guo; Pat B Zanzonico; Steven M Larson; Nai-Kong Cheung
Journal:  Mol Cancer Ther       Date:  2014-06-18       Impact factor: 6.261

8.  Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses.

Authors:  Sarah M Cheal; Michael R McDevitt; Brian H Santich; Mitesh Patel; Guangbin Yang; Edward K Fung; Darren R Veach; Meghan Bell; Afruja Ahad; Daniela Burnes Vargas; Blesida Punzalan; Naga Vara Kishore Pillarsetty; Hong Xu; Hong-Fen Guo; Sébastien Monette; Adam O Michel; Alessandra Piersigilli; David A Scheinberg; Ouathek Ouerfelli; Nai-Kong V Cheung; Steven M Larson
Journal:  Theranostics       Date:  2020-09-14       Impact factor: 11.556

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.